Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jun 2025 According to Neurocrine Biosciences media release, Nxera Pharma will receive US$15 Million from Neurocrine Biosciences following Dosing of First Patient in Phase 3 Trial of NBI-1117568
02 May 2025 Status changed from planning to recruiting, according to Neurocrine Biosciences media release.
30 Apr 2025 According to Neurocrine Biosciences media release, the company is initiating the Phase 3 study supported by positive top-line data from the Phase 2 clinical study

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com